ArticleAdvances in therapy2025

Healthcare Utilization, Costs, and Treatment Discontinuation in Adults with Episodic Migraine Initiating Galcanezumab Versus Rimegepant: A US Retrospective Claims Analysis.

Gilwan Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.